Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia

Abstract excerpt

The incidence of central nervous system (CNS) disease in adults with acute lymphoblastic leukemia (ALL) is 5%–15% at diagnosis and 5% at relapse with intrathecal chemotherapy (ITC).1, 2 CNS is a known sanctuary site of ALL, and leukemic infiltration into the CNS can lead to significant morbidity and mortality. Disease features such as hyperleukocytosis at presentation,3 common in Philadelphia chromosome-positive...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Lymphoblastic Leukemia research
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations